newsfilter
← Earnings
Earnings Releases·

OnKure Therapeutics — Third Quarter 2026 Earnings Summary

  • Cash reserves increased to $163.3 million as of September 30, 2026, from $59.1 million at year-end 2025, extending the cash runway into 2029.
  • Third-quarter net loss widened to $17.8 million ($0.36 per share) from $14.7 million ($1.09 per share) in the prior year period, driven by higher R&D and G&A expenses.
  • Management confirmed lead programs OKI-355 and OKI-345 remain on track for Investigational New Drug (IND) submissions in the first half of 2027.
  • Total operating expenses for the nine months ended September 30, 2026, rose to $51.9 million from $48.8 million in the same period last year.
Company
ONKURE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology